Shopping Cart
Remove All
Your shopping cart is currently empty
SNX631
Catalog No. T212842 Copy Product Info
😃Good
SNX631 is a potent and highly selective CDK8/19 mediator kinase inhibitor with an IC₅₀ of 10.3 nM in NF-κB-dependent cellular assays. Its activity is 6–10 times higher than that of Senexin B in all assays except DiscoverX active site-dependent competitive binding experiments. SNX631 exerts synergistic effects with lapatinib and trastuzumab in multiple HER2-positive breast cancer cell lines, reversing and preventing resistance to HER2-targeted therapy. The combination of trastuzumab (a HER2 monoclonal antibody) and SNX631 inhibits the phosphorylation of STAT1 and STAT3 at the S727 site and upregulates the expression of the tumor suppressor BTG2 in HER2-positive breast cancer cells. SNX631 partially inhibits the growth of lapatinib-sensitive and -resistant HER2-positive breast cancer xenografts, and its antitumor effect is significantly enhanced when combined with lapatinib, effectively overcoming lapatinib resistance.
SNX631
Copy Product Info😃Good
Catalog No. T212842
SNX631 is a potent and highly selective CDK8/19 mediator kinase inhibitor with an IC₅₀ of 10.3 nM in NF-κB-dependent cellular assays. Its activity is 6–10 times higher than that of Senexin B in all assays except DiscoverX active site-dependent competitive binding experiments. SNX631 exerts synergistic effects with lapatinib and trastuzumab in multiple HER2-positive breast cancer cell lines, reversing and preventing resistance to HER2-targeted therapy. The combination of trastuzumab (a HER2 monoclonal antibody) and SNX631 inhibits the phosphorylation of STAT1 and STAT3 at the S727 site and upregulates the expression of the tumor suppressor BTG2 in HER2-positive breast cancer cells. SNX631 partially inhibits the growth of lapatinib-sensitive and -resistant HER2-positive breast cancer xenografts, and its antitumor effect is significantly enhanced when combined with lapatinib, effectively overcoming lapatinib resistance.
Cas No. 868066-26-6
Product information is being updated, if you want to purchase, please click the bulk custom button.
Add to Quotation
Resource Download
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | SNX631 is a potent and highly selective CDK8/19 mediator kinase inhibitor with an IC₅₀ of 10.3 nM in NF-κB-dependent cellular assays. Its activity is 6–10 times higher than that of Senexin B in all assays except DiscoverX active site-dependent competitive binding experiments. SNX631 exerts synergistic effects with lapatinib and trastuzumab in multiple HER2-positive breast cancer cell lines, reversing and preventing resistance to HER2-targeted therapy. The combination of trastuzumab (a HER2 monoclonal antibody) and SNX631 inhibits the phosphorylation of STAT1 and STAT3 at the S727 site and upregulates the expression of the tumor suppressor BTG2 in HER2-positive breast cancer cells. SNX631 partially inhibits the growth of lapatinib-sensitive and -resistant HER2-positive breast cancer xenografts, and its antitumor effect is significantly enhanced when combined with lapatinib, effectively overcoming lapatinib resistance. |
| Molecular Weight | 438.55 |
| Formula | C22H26N6O2S |
| Cas No. | 868066-26-6 |
| Smiles | O=C(N)C=1SC2=NC=CC(=C2C1N)N3CCN(C4=CC=C(C=C4)C(=O)N(C)C)CCC3 |
| Relative Density. | no data available |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Citations
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy SNX631 | purchase SNX631 | SNX631 cost | order SNX631 | SNX631 chemical structure | SNX631 formula | SNX631 molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.